The rationale for the design begins with the tumor microenvironment itself. Immune checkpoint inhibitors have transformed outcomes for a subset of patients with non-small cell lung cancer, but durable responses remain confined to a minority, and one of the key reasons is the reversible polarization of tumor-associated macrophages. These cells, which are numerically dominant among immune infiltrates in solid tumors, tend to adopt an M2-like, immunosuppressive phenotype that dampens inflammation, promotes tissue remodeling, and shields tumor cells from cytotoxic lymphocytes. Rather than simply depleting these macrophages, the research team set out to hijack them, exploiting their phagocytic appetite and their expression of mannose receptors such as CD206 to make them take up, process, and present a tumor antigen.

The choice of antigen was equally deliberate. CLDN6 is a member of the claudin family, proteins that seal the gaps between epithelial and endothelial cells. In normal adults its expression is restricted to immune-privileged sites such as the placenta and testes, but it is re-expressed at high levels in ovarian, gastric, and lung cancers, where elevated levels correlate with shorter survival in lung adenocarcinoma. That profile makes it an attractive target for immunotherapy: a vaccine aimed at CLDN6 should generate potent anti-tumor immunity while minimizing off-target toxicity. The team engineered lung cancer cell lines to overexpress human CLDN6, confirming expression rates above 90 percent by flow cytometry before proceeding to animal studies.

Structurally, the nanovaccine is a self-assembling coordination polymer. Zinc nitrate and 2-methylimidazole crystallize in water into polyhedral ZIF-8 particles roughly 115 nanometers across, which are then coated with polyethyleneimine and mannose to yield Zn-MAN particles of about 132 nanometers. When CLDN6 is incorporated during assembly, the final Zn-MAN@CLDN6 particles grow to roughly 186 nanometers and take on a near-spherical shape with a negative surface charge. Inductively coupled plasma mass spectrometry and protein assays established the composition: the zinc scaffold accounts for about 67 percent of the mass, the mannose targeting layer about 25 percent, and the loaded CLDN6 antigen about 5 percent, with encapsulation efficiency reaching approximately 80 percent at optimal antigen concentrations.

The most elegant feature of the material is its pH responsiveness. At physiological pH 7.4, less than 20 percent of the CLDN6 cargo is released over 24 hours, protecting the antigen from nonspecific degradation in the bloodstream. But when the particles reach the acidic environment of a tumor, around pH 6.5, their edges begin to soften, and inside the lysosomes of macrophages, at pH 5, the imidazolate framework collapses entirely: zinc ion release approaches 80 percent within six hours and CLDN6 release reaches about 90 percent. Transmission electron microscopy captured this disintegration directly, showing intact spheres at neutral pH, partially disassembled particles at tumor-like acidity, and complete structural collapse under lysosomal conditions.

Once inside macrophages, the released zinc ions act as more than a delivery trigger; they function as an endogenous adjuvant. Zinc is known to amplify toll-like receptor 4 signaling, prompting macrophages to secrete inflammatory cytokines such as TNF-alpha and IL-1beta, and to upregulate the co-stimulatory molecules CD80 and CD86 that T cells require alongside antigen recognition. When the researchers chelated zinc with TPEN, the vaccine’s ability to drive M1 polarization and antigen presentation collapsed, confirming that the metal ion is not incidental but central to the immune activation. Treated macrophages showed sharply elevated expression of MHC class I and II molecules and the inflammatory cytokine IL-12, hallmarks of professional antigen-presenting cells.

Functionally, the reprogrammed macrophages became far more aggressive. Bone-marrow-derived macrophages conditioned with the vaccine engulfed tumor cells at significantly higher rates and showed a greater than sevenfold increase in tumor cell killing compared with untreated macrophages. When these educated macrophages were co-cultured with T cells, the lymphocytes responded with vigorous proliferation and copious interferon-gamma secretion, and the primed T cells subsequently killed CLDN6-expressing tumor cells with markedly enhanced efficiency, releasing granzyme B and perforin. Macrophage depletion experiments using an anti-CSF1R antibody substantially diminished the vaccine’s anti-tumor effect in mice, demonstrating that the therapeutic activity genuinely depended on macrophage targeting and reprogramming rather than any direct cytotoxicity of the particles themselves.

Single-cell RNA sequencing of treated tumors revealed the depth of the microenvironmental remodeling. In untreated mice, malignant cells dominated the tumor landscape; after vaccination, macrophages and CD8-positive T cells jointly formed the dominant population. The vaccine increased the proportion of M1-like macrophages expressing CD80, CD86, and CD40, raised antigen-presentation genes including CD74 and the MHC genes H2-Aa and H2-Ab1, and reduced the fraction of cancer cells expressing PD-L1. Cell-communication analysis identified two critical signaling axes: macrophage-derived CXCL16 engaging CXCR6 on effector CD8 T cells, which positions the killer cells within tumors, and IL-15 signaling through IL-15RA and the JAK3/STAT5 pathway, which supplies survival and proliferation signals that prevent T cell exhaustion. Blocking JAK3 pharmacologically with decernotinib impaired STAT5 phosphorylation and reduced T cell-mediated tumor killing, confirming the pathway’s importance.

The vaccine also softened the tumor’s physical defenses. Collagen I forms a dense stromal barrier that impedes T cell infiltration, and the single-cell data showed that collagen production was largely confined to tumor cells while matrix metalloproteinases came from other compartments. Zn-MAN@CLDN6 increased MMP-2 expression in cancer-associated fibroblasts while suppressing macrophage-derived MMP-9 through a zinc-dependent induction of the RNA-binding protein ZFP36L2, which represses the transcription factor BARX1. In macrophages lacking ZFP36L2, the vaccine could no longer drive M2-to-M1 repolarization, tying this transcriptional circuit directly to the therapeutic mechanism. The net effect was degradation of the collagenous matrix and improved access for cytotoxic lymphocytes to the tumor core.

In vivo, the results were striking. Three intravenous doses at weekly intervals produced the strongest tumor growth suppression of all tested regimens, with TUNEL staining revealing extensive apoptosis and Ki-67 staining showing curtailed proliferation. The effect was strictly dependent on CLDN6: efficacy was markedly reduced in wild-type tumors lacking the antigen. In a metastasis model, the vaccine inhibited the spread of tumor cells through the bloodstream, and when combined with anti-PD-1 antibody, two of five mice achieved complete tumor ablation. Importantly, the vaccine retained potent activity in humanized mice engrafted with human lung cancer cells, a critical preclinical benchmark for translation. The authors caution that challenges remain, including the variable cross-presentation capacity of different macrophage subsets, the long-term metabolic burden of zinc accumulation, and the theoretical risk of autoimmune reactions against CLDN6 in reproductive tissues. Nevertheless, the study elevates tumor-associated macrophages from passive antigen couriers to active architects of an immune-permissive microenvironment, and offers a blueprint for treating CLDN6-positive lung cancer that could extend to combination regimens with CAR-T or TCR-T cell therapies.

Subject of Research: A mannose-functionalized zinc metal-organic framework nanovaccine delivering CLDN6 antigen to reprogram tumor-associated macrophages for lung cancer immunotherapy

Article Title: A zinc organic metal skeleton vaccine for lung cancer treatment can stimulate strong innate and adaptive anti-tumor immunity

Article References: Liu, X., Zhang, X., Wang, Y., Wang, H., Mao, S., Li, M., & Liu, H. (2026). A zinc organic metal skeleton vaccine for lung cancer treatment can stimulate strong innate and adaptive anti-tumor immunity. Materials Today Bio, 41, Article 103719. https://doi.org/10.1016/j.mtbio.2026.103719

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103719

Keywords: nanovaccine, metal-organic framework, lung cancer, CLDN6, tumor-associated macrophages, macrophage reprogramming, CD8 T cells, CXCL16-CXCR6, IL-15 signaling, zinc ions, immune checkpoint blockade, tumor microenvironment

The appeal of this approach lies in its minimalism. Conventional nanovaccine platforms built from liposomes or PLGA polymers typically require additional targeting modifications, and even then they often lack intrinsic ability to awaken the innate immune system. The microbiota-derived exopolysaccharide sidesteps these problems entirely. Because it is amphiphilic, meaning it carries both water-loving and water-fearing regions, EPS233 spontaneously folds into spherical nanoparticles roughly 27 nanometers in diameter when dispersed in water. That size falls squarely within the range that drains efficiently into lymph nodes, the anatomical hubs where immune responses are orchestrated. Structural analysis revealed a mean molecular mass of about 77.6 kilodaltons and a backbone rich in mannose residues, a feature that would later prove central to its immunological activity.

To build the actual vaccine, the team combined EPS233 with two payloads: ovalbumin as a model tumor antigen and resiquimod, known as R848, a small-molecule agonist of the TLR7/8 innate immune receptors. Molecular docking simulations predicted spontaneous binding between the sugar and R848, with hydrogen bonds of 3.0 to 3.3 angstroms stabilizing the interaction, and hundred-nanosecond molecular dynamics simulations showed the three components coalescing into a stable nanocluster in water. The resulting formulation, EPS@R848/OVA, measured just over 37 nanometers in diameter and achieved encapsulation efficiencies of approximately 84 percent for both cargo types. Critically, release studies demonstrated pH-responsive behavior: at physiological pH the payloads stayed locked inside, but under the acidic conditions of cellular lysosomes more than half the antigen escaped within 24 hours, precisely where the vaccine needs to unload inside dendritic cells.

Safety concerns with R848 itself provided an early test of the platform’s value. Free R848 injected with antigen triggered a surge of circulating pro-inflammatory cytokines within six hours and temporary weight loss in mice, a warning sign of the systemic toxicity that has hampered TLR agonists in the clinic. The nanovaccine version produced no such storm, apparently because the sugar matrix retained the drug locally and released it gradually. In vitro tests confirmed negligible cytotoxicity toward dendritic cells and fibroblasts at therapeutic concentrations, and hemolysis assays showed the formulation was as gentle on red blood cells as saline.

Inside dendritic cells, the nanovaccine performed a coordinated ballet. Confocal microscopy tracked rapid internalization within four hours, followed by progressive escape from lysosomes between eight and twelve hours, a crucial step because antigens trapped in lysosomes are degraded rather than presented. Flow cytometry then showed markedly elevated surface expression of MHC-I molecules loaded with antigen fragments, along with the costimulatory molecules CD40, CD80, and CD86, and robust secretion of interferon-beta, IL-6, TNF-alpha, and IL-12p70. Western blotting revealed the underlying mechanism: the exopolysaccharide engages the C-type lectin receptor Dectin-2, activating the Syk-CARD9 signaling axis, while R848 simultaneously ignites the TLR7-MyD88-IRF7 pathway. These two routes converge synergistically to drive type I interferon production, which amplifies antigen cross-presentation to CD8-positive T cells. Transcriptomic profiling confirmed upregulation of Irf8 and Batf3, transcription factors that drive the differentiation of the cross-presenting dendritic cell subset essential for antitumor immunity.

In vivo imaging showed the nanovaccine lingering at the injection site for over 120 hours and arriving in draining lymph nodes within six hours, where it was preferentially swallowed by dendritic cells, macrophages, and B cells. Most strikingly, it was avidly taken up by the rare CD103-positive CD11b-negative conventional dendritic cell subset, the population best equipped to prime cytotoxic T lymphocytes. A simple mixture of the same three components failed to replicate any of this, underscoring that co-assembly into a single nanoparticle, not the ingredients alone, drives the effect. Adoptive transfer experiments using transgenic OT-I mice confirmed that vaccinated animals mounted far larger populations of effector and multifunctional CD8-positive T cells secreting both interferon-gamma and TNF-alpha, alongside robust Th1-oriented CD4 responses, germinal center B cell expansion, and strong antigen-specific IgG and IgG2b antibody titers.

When put to the test against melanoma, the nanovaccine delivered on its immunological promise. In prophylactic models, vaccinated mice challenged with B16F10-OVA melanoma cells showed the slowest tumor growth and roughly 52 percent lower tumor weight than mice receiving the individual components. In therapeutic settings with established tumors, the nanovaccine cut mean tumor volume by roughly half compared with single-adjuvant controls, while analyses of the tumor microenvironment revealed a fundamental remodeling: more activated CD8 and CD4 T cells producing interferon-gamma, TNF-alpha, and granzyme B, and fewer immunosuppressive regulatory T cells and myeloid-derived suppressor cells. The platform also proved versatile, working with a peptide antigen, GP33, to sharply reduce lung metastatic nodules in a metastatic melanoma model, suggesting applicability beyond any single tumor type.

The most clinically consequential result emerged from combining the nanovaccine with anti-PD-1 checkpoint blockade. Checkpoint inhibitors revolutionized oncology, but most patients with so-called cold tumors do not respond. In orthotopic B16F10-GP33 melanoma, the combination of EPS@R848/GP33 with anti-PD-1 antibody achieved near-complete tumor elimination, a 98.1 percent reduction in tumor weight, and extended median survival to 41 days versus 32 days with antibody alone. In the lung metastasis model, the combination inhibited tumor burden by 88.1 percent and prolonged survival to 33 days versus 25 days. The vaccine appears to convert immunologically quiet tumors into inflamed ones, providing the activated T cell infiltrate that PD-1 blockade needs to work, while simultaneously reducing T cell exhaustion markers and building systemic memory T cell populations that could guard against recurrence.

Throughout the study, safety data were reassuring. Repeated dosing produced no histopathological abnormalities in heart, liver, spleen, lung, or kidney, serum biochemistry remained normal, and long-term follow-up four weeks after the final immunization showed intact organ architecture. The authors acknowledge that the work so far rests on surrogate antigens in melanoma models, and that testing with true tumor-associated antigens and personalized neoantigens will be the decisive next step. Even so, the study establishes a compelling proof of concept: a sugar made by a probiotic bacterium, requiring no chemical conjugation, no synthetic polymer, and no external targeting ligand, can serve as a complete, self-adjuvanting vaccine platform. As cancer vaccines move toward individually tailored neoantigens, a simple, scalable carrier that integrates delivery and innate activation in one molecule could become a foundational tool for the next generation of immunotherapy.

Subject of Research: A microbiota-derived exopolysaccharide nanovaccine that co-delivers tumor antigen and a TLR7 agonist to boost antitumor immunity

Article Title: Microbiota-derived self-adjuvanting exopolysaccharide-based codelivery system for potent cancer immunotherapy

Article References: Microbiota-derived self-adjuvanting exopolysaccharide-based codelivery system for potent cancer immunotherapy. (n.d.). https://doi.org/10.1016/j.mtbio.2026.103677

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103677

Keywords: cancer immunotherapy, nanovaccine, exopolysaccharide, microbiota, dendritic cells, TLR7 agonist, R848, anti-PD-1, melanoma, CD8 T cells, lymph node targeting, drug delivery